EFAVIRENZ TABLET FORMULATION HAVING UNIQUE BIOPHARMACEUTICAL CHARACTERISTICS

摘要

The present invention provides an efavirenz tablet formulation which, when administered as a single dose to a subject, provides a mean maximum plasma concentration (Cmax) of about 4microM to about 14microM, a mean time of maximum plasma concentration (Tmax) of about 2 hours to about 5 hours, and a mean area under the plasma concentration versus time curve from time zero to time infinity (AUC) of about 190microM/hour to about 470microM/hour.